Guardant Health CCO sells 24,406 shares after exercise

Guardant Health Chief Commercial Officer Chris Freeman exercised options to acquire 24,406 shares of common stock at $32.86 per share and on the same day completed an open-market sale of 24,406 shares at a weighted average price of $118.6741.

Rhea-AI Filing Summary

Guardant Health Chief Commercial Officer Chris Freeman exercised options to acquire 24,406 shares of common stock at $32.86 per share and on the same day completed an open-market sale of 24,406 shares at a weighted average price of $118.6741.

After these transactions, Freeman directly holds 60,034 shares of common stock and 701 remaining stock options with a $32.86 exercise price expiring on June 9, 2033. The exercised options come from a June 9, 2023 award that vests over three years.

Insider Trade Summary

Exercise and Sale: 24,406 shares ($2.09M approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Freeman Chris

Role Chief Commercial Officer

Sold 24,406 shs ($2.90M)

Approx. gross sale proceeds $2.90M

Approx. exercise cost $802K

Approx. pre-tax spread $2.09M

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	24,406	$0.00	$0.00
Exercise	Common Stock	24,406	$32.86	$802K
Sale	Common Stock	24,406	$118.6741	$2.90M

Holdings After Transaction: Stock Option (Right to Buy) — 701 contracts (Direct); Common Stock — 60,034 shares (Direct)

Footnotes (2)

1. F1. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $118.55 to $118.97. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
2. F2. This represents a stock option award granted on June 9, 2023 that vests over a three-year period. 33% of the shares subject to such award vested on June 9, 2024 and the remaining 67% of the shares subject to award vests each month during the two-year period thereafter.

Key Figures

Shares sold: 24,406 shares Sale price: $118.6741 per share Options exercised: 24,406 shares +4 more

7 metrics

Shares sold 24,406 shares Open-market sale of common stock on May 22, 2026

Sale price $118.6741 per share Weighted average sale price for 24,406 shares

Options exercised 24,406 shares Common stock acquired via option exercise on May 22, 2026

Exercise price $32.86 per share Stock option exercise price for 24,406 shares

Shares held after 60,034 shares Direct common stock holdings following transactions

Remaining options 701 options Stock options remaining after exercise, expiring June 9, 2033

Option expiration June 9, 2033 Expiration date for remaining stock options

Key Terms

open-market sale, Stock Option (Right to Buy), weighted average sales price per share, stock option award

4 terms

open-market sale financial

"transaction_action: "open-market sale" for 24,406 common shares"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)" with underlying common stock"

weighted average sales price per share financial

"Represents the weighted average sales price per share. These shares were sold in multiple transactions"

stock option award financial

"This represents a stock option award granted on June 9, 2023 that vests over a three-year period"

A stock option award is a grant that gives an employee the right to buy a company’s shares at a fixed price for a limited time, often becoming available gradually over a set schedule. Investors care because these awards align workers’ incentives with company performance, can increase employee loyalty, and may create future share dilution and compensation expense that affect earnings per share and shareholder value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Guardant Health (GH) report for Chris Freeman?

Guardant Health reported that Chief Commercial Officer Chris Freeman exercised options for 24,406 shares at $32.86 and sold 24,406 shares in an open-market transaction at a weighted average price of $118.6741, leaving him with 60,034 shares.

How many Guardant Health (GH) shares did Chris Freeman sell and at what price?

Chris Freeman sold 24,406 Guardant Health common shares in an open-market transaction at a weighted average price of $118.6741 per share, with individual trades occurring between $118.55 and $118.97 as disclosed in the filing footnote.

What stock options did Chris Freeman exercise at Guardant Health (GH)?

Freeman exercised stock options covering 24,406 Guardant Health shares at an exercise price of $32.86 per share. These options were part of a June 9, 2023 award that vests over three years, with 33% vesting in 2024 and the rest monthly thereafter.

How many Guardant Health (GH) shares does Chris Freeman hold after the Form 4?

Following the reported transactions, Chris Freeman directly holds 60,034 shares of Guardant Health common stock. He also retains 701 stock options with a $32.86 exercise price that are scheduled to expire on June 9, 2033, according to the Form 4 data.

Does Chris Freeman still have unexercised Guardant Health (GH) stock options?

Yes. After exercising 24,406 options, Chris Freeman still holds 701 stock options with a $32.86 exercise price. These options relate to a June 9, 2023 grant and carry an expiration date of June 9, 2033 as disclosed in the filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/26/2026 - 05:38 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Freeman Chris

(Last) (First) (Middle)

3100 HANOVER STREET

(Street)

PALO ALTO CALIFORNIA 94304

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/22/2026		M		24,406	A	$32.86	84,440	D
Common Stock	05/22/2026		S		24,406	D	$118.6741(1)	60,034	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$32.86	05/22/2026		M			24,406	(2)	06/09/2033	Common Stock	24,406	$0	701	D

Explanation of Responses:

1. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $118.55 to $118.97. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

2. This represents a stock option award granted on June 9, 2023 that vests over a three-year period. 33% of the shares subject to such award vested on June 9, 2024 and the remaining 67% of the shares subject to award vests each month during the two-year period thereafter.

Remarks:

	/s/ John G. Saia, as attorney-in-fact for Chris Freeman	05/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)